205535-92-8 Usage
Description
(2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL)-CARBAMIC ACID BENZYL ESTER is a carbamic acid ester compound that features a carbamic acid group, an ethyl group, and a benzyl group. It also contains three ethoxy groups and a hydroxy-ethoxy group. This versatile chemical has potential applications in the pharmaceutical industry and can be utilized in the synthesis of various organic compounds. Careful handling and storage are necessary due to its specific requirements.
Uses
Used in Pharmaceutical Industry:
(2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL)-CARBAMIC ACID BENZYL ESTER is used as a chemical intermediate for the development and synthesis of pharmaceutical compounds. Its unique structure allows it to be a key component in creating new drugs and medications.
Used in Organic Synthesis:
In the field of organic chemistry, (2-[2-(2-HYDROXY-ETHOXY)-ETHOXY]-ETHYL)-CARBAMIC ACID BENZYL ESTER is used as a building block for synthesizing a variety of organic compounds. Its diverse functional groups enable it to participate in numerous chemical reactions, contributing to the creation of complex molecules for various applications.
Check Digit Verification of cas no
The CAS Registry Mumber 205535-92-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,5,5,3 and 5 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 205535-92:
(8*2)+(7*0)+(6*5)+(5*5)+(4*3)+(3*5)+(2*9)+(1*2)=118
118 % 10 = 8
So 205535-92-8 is a valid CAS Registry Number.
InChI:InChI=1/C14H21NO5/c16-7-9-19-11-10-18-8-6-15-14(17)20-12-13-4-2-1-3-5-13/h1-5,16H,6-12H2,(H,15,17)
205535-92-8Relevant articles and documents
SYNTHETIC PROCESSES AND INTERMEDIATES
-
Page/Page column 33-34, (2021/06/26)
The invention provides synthetic processes and synthetic intermediate compounds that can be used to prepare therapeutic conjugates. The invention also provides methods for treating HBV and/or HDV infection in a human by administering a therapeutic conjugate prepared by the synthetic methods of the invention.
BIVALENT TARGETED CONJUGATES
-
Page/Page column 40; 41, (2020/05/28)
The invention provides conjugates that comprise a bivalent targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates, compositions comprising the bidentate targeting ligands and the conjugates, as well as methods for targeting therapeutic nucleic acids with the bidentate conjugates. The conjugates are useful to target therapeutic nucleic acids.
PROTAC-mediated crosstalk between E3 ligases
Steinebach, Christian,Kehm, Hannes,Lindner, Stefanie,Vu, Lan Phuong,K?pff, Simon,López Mármol, álvaro,Weiler, Corinna,Wagner, Karl G.,Reichenzeller, Michaela,Kr?nke, Jan,Gütschow, Michael
, p. 1821 - 1824 (2019/02/12)
Small-molecule heterobifunctional degraders can effectively control protein levels and are useful research tools. We assembled proteolysis targeting chimeras (PROTACs) from a cereblon (CRBN) and a von-Hippel-Lindau (VHL) ligase ligand and demonstrated a PROTAC-induced heterodimerization of the two E3 ligases leading to unidirectional and efficient degradation of CRBN.
